drugset / Trial / NCT01017614
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the trial is to demonstrate that intravenous iron oligosaccharide is non-inferior to oral iron sulphate in reducing iron deficiency anaemia secondary to inflammatory bowel disease (IBD), evaluated as the ability to increase haemoglobin (Hb).
Timeline
- Start
- 2009-10
- Primary completion
- 2012-07
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Iron Sulfate | Small molecule | 200 mg | Oral |
| Subject | Iron isomaltoside 1000 | Unknown | — | Intravenous |